Company intelligence / Profile preview

Remix Therapeutics

Watertown, Massachusetts, USAremixlabs.com ↗

Ownership: Private
Development stage: Other

Overview

Remix Therapeutics is developing small molecule therapies that modulate RNA processing to address disease drivers. The company leverages its proprietary REMaster platform to identify and optimize compounds targeting previously undruggable mechanisms. As of mid-2025, it has multiple programs progressing toward or in early clinical development; detailed clinical results have not been published yet.

Therapeutic areas: OncologyRare DiseasesNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

No major pharmaceutical partnerships have been publicly announced as of June 2025. The company does engage in strategic collaborations with academic institutions and may pursue future pharma partnerships for commercialization/licensing

Beyond the preview

Go deeper on Remix Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Remix Therapeutics.

Explore the full profile